BOSTON, MA, Abata Therapeutics has launched with $95 million in Series A funding led by Third Rock Ventures.
Third Rock Ventures announced the launch of Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with progressive multiple sclerosis (MS) and other severe autoimmune and inflammatory diseases.
The company- first seeded by Third Rock Ventures and ElevateBio- has secured $95 million in Series A funding led by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital and the JDRF T1D Fund.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
